ABBVIE
Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 130
- Registration Number
- NCT02305758
Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT02296905
- Locations
- 🇳🇿
Site Reference ID/Investigator# 130590, Grafton, New Zealand
🇺🇸Site Reference ID/Investigator# 130588, San Antonio, Texas, United States
🇺🇸Site Reference ID/Investigator# 130589, Miami, Florida, United States
A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 70
- Registration Number
- NCT02292719
Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 221
- Registration Number
- NCT02289690
- Locations
- 🇨🇿
Vitkovicka nemocnice a. s. /ID# 149839, Ostrava, Czechia
🇰🇷Chonnam National University Hwasun Hospital /ID# 153188, Jeonnam, Korea, Republic of
🇺🇸Georgia Regents University /ID# 148567, Augusta, Georgia, United States
Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease
- Conditions
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 62
- Registration Number
- NCT02289729
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 94
- Registration Number
- NCT02287233
- Locations
- 🇺🇸
Univ Kansas Med Ctr /ID# 131175, Kansas City, Kansas, United States
🇺🇸Vanderbilt University Medical Center /ID# 131177, Nashville, Tennessee, United States
🇺🇸Weill Cornell Medical College /ID# 131170, New York, New York, United States
Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
- Conditions
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2016-07-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 359
- Registration Number
- NCT02282982
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 38
- Registration Number
- NCT02265731
- Locations
- 🇯🇵
Nagoya City University Hospital /ID# 129278, Nagoya shi, Aichi, Japan
🇯🇵NHO Nagoya Medical Center /ID# 129222, Nagoya-shi, Aichi, Japan
🇯🇵Osaka University Hospital /ID# 169862, Suita-shi, Osaka, Japan
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
- Conditions
- Interventions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 595
- Registration Number
- NCT02264990
- Locations
- 🇨🇿
Multiscan s.r.o. /ID# 132689, Pardubice, Czechia
🇩🇪Klinik Loewenstein GmbH /ID# 131925, Löwenstein, Germany
🇹🇷Inonu University /ID# 136569, Malatya, Turkey
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
- Conditions
- Interventions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 184
- Registration Number
- NCT02265237